Investor Relations - Curis

Month Year

Investor Alerts

Sep 2, 2015

Curis to Participate in Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Jul 30, 2015

Curis to Release Second Quarter 2015 Financial Results and Hold Conference Call on August 6, 2015

LEXINGTON, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Jul 6, 2015

Curis Reports Second Quarter 2015 Financial Results

Management to Host Conference Call Today at 8:30 a.m. EDT

LEXINGTON, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Jun 10, 2015

Curis to Present CUDC-907 Clinical Data at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma

LEXINGTON, Mass., June 10, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
May 31, 2015

Curis Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting

CUDC-907 (HDAC and PI3K Inhibitor) Demonstrates Objective Responses, Including Complete Responses, in Patients With Relapsed/ Refractory DLBCL

LEXINGTON, Mass., May 31, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
May 26, 2015

Curis to Present at the Jefferies 2015 Healthcare Conference

LEXINGTON, Mass., May 27, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
May 20, 2015

Curis Announces Presentations of CUDC-907 and Erivedge(R) Clinical Data at 2015 ASCO Annual Meeting

LEXINGTON, Mass., May 20, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
May 7, 2015

Curis Reports First Quarter 2015 Financial Results

Management to Host Conference Call Today at 8:30 a.m. EDT

LEXINGTON, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Apr 30, 2015

Curis to Release First Quarter 2015 Financial Results and Hold Conference Call on May 7, 2015

LEXINGTON, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Apr 22, 2015

Curis Presents Preclinical Data on CUDC-427 at AACR Annual Meeting

Collaborator Aurigene Presents Data From Its IRAK-4 Program

LEXINGTON, Mass., April 22, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Apr 14, 2015

Curis Announces Presentation of Data from CUDC-427 and IRAK-4 Programs at AACR Annual Meeting

LEXINGTON, Mass., April 14, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Apr 5, 2015

Curis Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B-Cell Lymphoma

LEXINGTON, Mass., April 6, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Mar 3, 2015

Curis to Present at the 27th Annual Roth Conference

LEXINGTON, Mass., March 3, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Mar 2, 2015

Curis Announces Closing of Public Offering of Common Stock

LEXINGTON, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), announced today the closing of its previously announced public offering of common stock. Curis sold 25,090,908 shares...
Feb 25, 2015

Curis Prices Public Offering of Common Stock

LEXINGTON, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), announced today the pricing of an underwritten registered public offering of 21,818,181 shares of its common stock at...
Feb 25, 2015

Curis to Present at the Cowen and Company 35th Annual Health Care Conference

LEXINGTON, Mass., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Feb 24, 2015

Curis Reports Fourth Quarter and Year-End 2014 Financial Results

LEXINGTON, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Feb 24, 2015

Curis Announces Proposed Public Offering of Common Stock

LEXINGTON, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), announced today that it has commenced an underwritten public offering of shares of its common stock. In connection...
Feb 3, 2015

Curis to Present at the 2015 Bio CEO and Investor Conference

LEXINGTON, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Jan 21, 2015

Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets

Agreement Provides Curis with Option to Exclusively License Aurigene's Antagonists for Immuno-Oncology, Including an Antagonist of PD-L1 and Selected Precision Oncology Targets, Including an IRAK4 Kinase Inhibitor

LEXINGTON, Mass. and BANGALORE, India, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug...
Nov 26, 2014

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Nov 17, 2014

Curis Announces Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients With Advanced/ Relapsed Solid Tumors

Trial Expected to Enroll Patients With Hormone Receptor Positive Breast Cancer and Patients With Midline Carcinoma With NUT Rearrangement

LEXINGTON, Mass., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Nov 12, 2014

Curis to Present at the Stifel 2014 Healthcare Conference

LEXINGTON, Mass., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Nov 10, 2014

Curis Reports Third Quarter 2014 Financial Results and Pipeline Update

Curis Provides Summary From Dose Escalation Stage of CUDC-907 Phase 1 Study Supporting Ongoing Expansion in DLBCL Patients

LEXINGTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Nov 3, 2014

Curis to Release Third Quarter 2014 Financial Results and Hold Conference Call on November 10, 2014

LEXINGTON, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that...
Oct 28, 2014

Curis Announces Allowance of U.S. Patent Covering Compounds Targeting HDAC and PI3K Activities in a Single Molecule

LEXINGTON, Mass., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Oct 2, 2014

Curis Announces CUDC-907 Development Program Advancements

Expansion cohorts opened to enroll patients with relapsed/refractory Diffuse Large B-Cell Lymphoma and Multiple Myeloma

LEXINGTON, Mass., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Sep 3, 2014

Curis to Present at the 13th Annual BIO Investor Forum

LEXINGTON, Mass., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Aug 27, 2014

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Aug 7, 2014

Curis Reports Second Quarter 2014 Financial Results

Management to Host Conference Call Today at 9:00 a.m. EDT

LEXINGTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Jul 31, 2014

Curis to Release Second Quarter 2014 Financial Results and Hold Conference Call on August 7, 2014

LEXINGTON, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Jun 23, 2014

Curis Announces Investigational New Drug Application Filing by Roche to Initiate a Phase 2 Study of Erivedge(R) (vismodegib) in Idiopathic Pulmonary Fibrosis

Filing Triggers $3 Million Milestone Payment to Curis

LEXINGTON, Mass., June 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Jun 5, 2014

Curis Announces Re-Initiation of Patient Dosing in CUDC-427 Monotherapy Clinical Trial

Expansion Phase to Include Patients With Ovarian Cancer and Certain Hematologic Malignancies

LEXINGTON, Mass., June 5, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Jun 3, 2014

Curis Announces Executive Management Transition

Ali Fattaey, Ph.D. Promoted to President and Chief Executive Officer

LEXINGTON, Mass., June 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced the...
May 29, 2014

Curis to Present at the Jefferies 2014 Global Healthcare Conference

LEXINGTON, Mass., May 29, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that...
May 23, 2014

Curis Announces Abstracts for Its Partnered Programs, Erivedge(R) and Debio 0932 to be Presented at the 2014 ASCO Annual Meeting

LEXINGTON, Mass., May 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
May 18, 2014

Curis to Present at the JMP Securities Healthcare Conference

LEXINGTON, Mass., June 18, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that...
May 8, 2014

Curis Reports First Quarter 2014 Financial Results

Management to Host Conference Call Today at 9:00 a.m. EDT

LEXINGTON, Mass., May 8, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company developing novel drug candidates for the treatment of human cancers, today...
May 1, 2014

Curis to Release First Quarter 2014 Financial Results and Hold Conference Call on May 8, 2014

LEXINGTON, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Apr 30, 2014

Curis to Present at the Deutsche Bank 39th Annual Health Care Conference

LEXINGTON, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Apr 30, 2014

Curis Announces U.S. Patent Issuance Covering CUDC-907 Composition-of-Matter

Dual HDAC and PI3K Inhibitor in Ongoing Phase 1 Study in Patients With Relapsed/ Refractory Lymphoma and Multiple Myeloma

LEXINGTON, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Apr 7, 2014

Curis and Debiopharm Group(TM) Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014

Debio 0932 Demonstrated Anti-Tumor Activity and Synergy With Various SOC Agents in In Vitro and Xenograft Models of NSCLC and RCC

LAUSANNE, Switzerland and LEXINGTON, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of...
Apr 7, 2014

Curis Reports CUDC-907 and CUDC-427 Data at AACR Annual Meeting 2014

CUDC-907 Modulates Expression of Certain Cytokines/ Chemokines, Potentially Targeting Tumor Microenvironment in Addition to Direct Effects on Cancer Cells

LEXINGTON, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Apr 2, 2014

Curis to Present at the 13th Annual Needham Healthcare Conference

LEXINGTON, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Mar 31, 2014

Curis Announces Removal of FDA Partial Clinical Hold on CUDC-427

Curis Expects to Reinitiate Enrollment in Single Agent Phase 1 Study of CUDC-427 in Patients With Solid Tumors or Lymphoma

LEXINGTON, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Mar 30, 2014

Curis Announces Presentation of Data for CUDC-907, CUDC-427 and Debio 0932 at AACR Annual Meeting

LEXINGTON, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Mar 4, 2014

Curis to Present at the 26th Annual ROTH Conference

LEXINGTON, Mass., March 4, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Feb 23, 2014

Curis to Present at the Cowen and Company 34th Annual Health Care Conference

LEXINGTON, Mass., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Feb 20, 2014

Curis Reports Fourth Quarter and Year-End 2013 Financial Results

Management to Host Conference Call Today at 9:00 a.m. EST

LEXINGTON, Mass., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Feb 19, 2014

Curis to Present at the RBC Capital Markets Global Healthcare Conference

LEXINGTON, Mass., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...

Show per page